Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug Administration licenced sirolimus protein-bound partic...
recist
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or ...
recist
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after ...
recist